MCID: VSC008
MIFTS: 32

Vascular Hemostatic Disease

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Vascular Hemostatic Disease

MalaCards integrated aliases for Vascular Hemostatic Disease:

Name: Vascular Hemostatic Disease 12 14
Vascular Hemostatic Disorders 69
Hemostatic Disorders 42

Classifications:



External Ids:

Disease Ontology 12 DOID:484
MeSH 42 D020141
SNOMED-CT 64 21112004
UMLS 69 C0600502

Summaries for Vascular Hemostatic Disease

MalaCards based summary : Vascular Hemostatic Disease, also known as vascular hemostatic disorders, is related to thrombophilia due to activated protein c resistance and alcoholic psychosis. An important gene associated with Vascular Hemostatic Disease is KRIT1 (KRIT1, Ankyrin Repeat Containing), and among its related pathways/superpathways is Complement and coagulation cascades. The drugs Bortezomib and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotype is embryo.

Related Diseases for Vascular Hemostatic Disease

Diseases related to Vascular Hemostatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
id Related Disease Score Top Affiliating Genes
1 thrombophilia due to activated protein c resistance 31.1 F2 SERPINC1
2 alcoholic psychosis 10.7 KRIT1 SNRPB
3 lipoadenoma 10.7 KRIT1 SNRPB
4 adult central nervous system choriocarcinoma 10.7 KRIT1 SNRPB
5 thrombophilia due to protein c deficiency, autosomal dominant 10.7
6 thrombophilia due to protein c deficiency, autosomal recessive 10.7
7 thrombophilia due to protein s deficiency, autosomal dominant 10.7
8 thrombophilia due to hrg deficiency 10.7
9 thrombophilia due to thrombomodulin defect 10.7
10 thrombophilia, x-linked, due to factor ix defect 10.7
11 thrombophilia due to antithrombin iii deficiency 10.7
12 thrombophilia due to heparin cofactor ii deficiency 10.7
13 tactile epilepsy 10.6 HBA1 KRIT1
14 syncope 10.3 F2 SERPINC1
15 pyridoxine deficiency anemia 10.3 F2 SERPINC1
16 fragile x syndrome type 2 10.3 F2 SERPINC1
17 superior limbic keratoconjunctivitis 10.3 F2 SERPINC1
18 follicular adenoma 10.3 F2 SERPINC1
19 myiasis 10.3 F2 SERPINC1
20 testicular gonadoblastoma 10.3 F2 SERPINC1
21 egg allergy 10.3 F2 SERPINC1
22 rectum neuroendocrine neoplasm 10.3 F2 SERPINC1
23 syndactyly, mesoaxial synostotic, with phalangeal reduction 10.3 F2 SERPINC1
24 midline cystocele 10.3 F2 SERPINC1
25 collagenous colitis 10.3 F2 SERPINC1
26 littre gland carcinoma 10.3 F2 SERPINC1
27 hiv-1 10.2 F2 SERPINC1
28 glutathioninuria 10.2 F2 SERPINC1
29 inferolateral myocardial infarct 10.2 F2 SERPINC1
30 lymphatic system cancer 10.2 F2 SERPINC1
31 rheumatoid lung disease 10.2 F2 SERPINC1
32 hemopneumothorax 10.2 F2 HBA1 KRIT1
33 angelucci's syndrome 10.2 F2 SERPINC1
34 lethal congenital contracture syndrome 10.2 F2 SERPINC1
35 lujo hemorrhagic fever 10.2 F2 SERPINC1
36 cryptosporidiosis 10.2 F2 SERPINC1
37 essential thrombocythemia 10.2 F2 SERPINC1
38 spinal cord lipoma 10.2 F2 SERPINC1
39 intestinal pseudo-obstruction 10.2 F2 SERPINC1
40 congenital syphilis 10.2 F2 SERPINC1
41 neuroaxonal dystrophy 10.2 F2 SERPINC1
42 childhood brain stem glioma 10.2 F2 SERPINC1
43 central retinal artery occlusion 10.2 F2 SERPINC1
44 angular blepharoconjunctivitis 10.2 F2 SERPINC1
45 hepadnavirus infection 10.2 F2 SERPINC1
46 dysgammaglobulinemia 10.2 F2 SERPINC1
47 capillary hemangioma 10.2 F2 SERPINC1
48 dyskeratosis congenita autosomal recessive 10.2 F2 SERPINC1
49 ulcerative stomatitis 10.1 F2 SERPINC1
50 blepharoconjunctivitis 10.1 F2 SERPINC1

Graphical network of the top 20 diseases related to Vascular Hemostatic Disease:



Diseases related to Vascular Hemostatic Disease

Symptoms & Phenotypes for Vascular Hemostatic Disease

MGI Mouse Phenotypes related to Vascular Hemostatic Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.1 CCM2 CR1L F2 KRIT1 PDCD10 SERPINC1

Drugs & Therapeutics for Vascular Hemostatic Disease

Drugs for Vascular Hemostatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 779)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
3
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
5
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
6
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
7
Warfarin Approved Phase 4,Phase 3,Phase 1 81-81-2 6691 54678486
8
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3 1197-18-8 5526
9
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 191732-72-6 216326
10
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
11
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 148-82-3 4053 460612
12
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
14
Panobinostat Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 404950-80-7 6918837
15
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
18
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
19
Thrombin Approved Phase 4,Phase 3,Phase 2
20
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
21
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
22
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
23
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
24
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
25
Apixaban Approved Phase 4,Phase 3,Phase 2 503612-47-3 10182969
26
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
27
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
28
Acenocoumarol Approved Phase 4 152-72-7 9052 54676537
29
Phenindione Approved Phase 4 83-12-5 4760
30
Celiprolol Approved, Investigational Phase 4 56980-93-9
31
Phentolamine Approved Phase 4 50-60-2 5775
32 Thiotepa Approved Phase 4,Phase 2,Phase 1 52-24-4 5453
33 Ixazomib Approved Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
34
Menthol Approved Phase 4,Phase 1 2216-51-5 16666
35
Menadione Approved, Nutraceutical Phase 4,Phase 3 58-27-5 4055
36
Phytonadione Approved, Nutraceutical Phase 4,Phase 3 84-80-0 4812 5284607
37
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
38
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
39
Pirarubicin Investigational Phase 4 72496-41-4
40 fluindione Investigational Phase 4 957-56-2
41 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
43 Blood Substitutes Phase 4,Phase 3,Phase 2
44 Hydroxyethyl Starch Derivatives Phase 4,Phase 2
45 Plasma Substitutes Phase 4,Phase 3,Phase 2
46 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2649)

id Name Status NCT ID Phase Drugs
1 The Effect of Human Albumin on Coagulation Competence and Hemorrhage Unknown status NCT02270723 Phase 4 5% Human Albumin " Behring";Lactated Ringer
2 Study Using Plasma for Patients Requiring Emergency Surgery Unknown status NCT01221389 Phase 4 Human Plasma
3 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
4 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
5 Pseudohyponatremia of Multiple Myeloma is True Hyponatremia Unknown status NCT01425606 Phase 4
6 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
7 Free Fatty Acid-Induced Hypertension in Obese Subjects With Type 2 Diabetes Completed NCT00738023 Phase 4 Rosiglitazone;Normal saline 0.9%;Intralipid 20%
8 Goal-orientated Therapy of Perioperative Disturbance in Hemostasis in Cardiac Surgery Completed NCT00516126 Phase 4
9 Anticoagulant Clinics and Vitamin K Antagonists Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
10 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Completed NCT02009033 Phase 4 Lactated Ringer;Hydroxyethylstarch
11 The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass Completed NCT01435304 Phase 4
12 Hemodilution and Coagulopathy With 3 Colloids Completed NCT01727830 Phase 4
13 The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
14 Comparison of Three Management Strategies for Post Cardiac Surgery Bleeding Completed NCT00188747 Phase 4
15 Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study. Completed NCT01487837 Phase 4 Human fibrinogen concentrate
16 Fibrinogen as an Alternative to FFP in Aortic Surgery. Completed NCT00994045 Phase 4
17 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
18 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
19 Trial of NovoSeven® in Haemophilia - Joint Bleeds Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
20 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) Completed NCT00168090 Phase 4 Blood coagulation Factor VIII and vWF, human
21 Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type Completed NCT00190411 Phase 4 celiprolol;Control
22 Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia Completed NCT00230659 Phase 4
23 Retrospective Survey of Re-treatment With Bortezomib Completed NCT01524445 Phase 4
24 A Multiple Myeloma Trial in Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
25 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone
26 An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade Completed NCT01675245 Phase 4 No intervention
27 Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients. Completed NCT01026701 Phase 4 bortezomib
28 A Retreatment Study With Bortezomib for Multiple Myeloma Completed NCT01030302 Phase 4 bortezomib
29 A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure Completed NCT01241396 Phase 4
30 Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma Completed NCT02474563 Phase 4 Bortezomib;Melphalan;Prednisone
31 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Patients Completed NCT00622505 Phase 4 zoledronic acid
32 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
33 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
34 Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma Completed NCT01083602 Phase 4 panobinostat;bortezomib;dexamethasone
35 Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib Completed NCT01060202 Phase 4 No intervention
36 Quality of Life in Multiple Myeloma Patients Treated With Bortezomib Completed NCT01021592 Phase 4 bortezomib
37 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
38 VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands Completed NCT00440765 Phase 4 bortezomib
39 ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies. Completed NCT00440479 Phase 4 Bortezomib
40 Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability Completed NCT00257114 Phase 4 bortezomib
41 Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS) Completed NCT01005628 Phase 4 bortezomib
42 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
43 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
44 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis Completed NCT03222687 Phase 4 tacrolimus;prednisone
45 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
46 HSP-glomerulonephritis Trial: MP vs CyA Completed NCT00425724 Phase 4 Methylprednisolone pulses plus prednisone versus Cyclosporine A
47 PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
48 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
49 Pilot Study to Compare Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months Recruiting NCT02774317 Phase 4
50 Octaplas Pediatric Plasma Replacement Trial Recruiting NCT02050841 Phase 4

Search NIH Clinical Center for Vascular Hemostatic Disease

Cochrane evidence based reviews: hemostatic disorders

Genetic Tests for Vascular Hemostatic Disease

Anatomical Context for Vascular Hemostatic Disease

MalaCards organs/tissues related to Vascular Hemostatic Disease:

39
Bone, Bone Marrow, B Cells, T Cells, Testes, Kidney, Liver

Publications for Vascular Hemostatic Disease

Variations for Vascular Hemostatic Disease

Expression for Vascular Hemostatic Disease

Search GEO for disease gene expression data for Vascular Hemostatic Disease.

Pathways for Vascular Hemostatic Disease

Pathways related to Vascular Hemostatic Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.94 C1QC F2 SERPINC1

GO Terms for Vascular Hemostatic Disease

Cellular components related to Vascular Hemostatic Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.5 C1QC CD2AP F2 HBA1 PDCD10 SERPINC1
2 blood microparticle GO:0072562 8.92 C1QC F2 HBA1 SERPINC1

Biological processes related to Vascular Hemostatic Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hemostasis GO:0007599 9.16 F2 SERPINC1
2 positive regulation of protein localization to nucleus GO:1900182 8.96 CD2AP F2
3 regulation of blood coagulation GO:0030193 8.62 F2 SERPINC1

Sources for Vascular Hemostatic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....